The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.00
Ask: 42.00
Change: -1.00 (-2.38%)
Spread: 2.00 (5.00%)
Open: 42.00
High: 42.00
Low: 41.00
Prev. Close: 42.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UN awards $250,000 grant to AquaInSilico

9 Mar 2021 07:00

RNS Number : 6090R
Frontier IP Group plc
09 March 2021
 

REACH - non-regulatory announcement

AIM: FIPP

09 March 2021

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

 

Portfolio news - United Nations awards $250,000 grant to AquaInSilico to help protect one of the world's most diverse marine environments

 

 

Frontier IP, a specialist in commercialising intellectual property ("IP"), today announces that portfolio company AquaInSilico ("AquaInSilico" or the "Company") has been selected to receive $250,000 as an 'Ocean Innovator' through the United Nations Development Programme's Ocean Innovation Challenge. The two-year project will help protect and conserve the coastal marine environment around the Cape Verde archipelago, West Africa.

 

AquaInSilico's role in the two-year project, called Phos-Value, will be to use its digital tools to design and implement improvements to wastewater treatment plants on the islands to reduce the amount of nutrients, such as nitrogen and phosphorus, entering the sea, and to improve the quality of water provided to Cape Verde's population.

 

If nutrient levels are too high in water, it causes excessive growth of algae, including the growth of nuisance species, in a process called marine eutrophication. This can result in less sunlight reaching the ocean floor and reduced oxygen levels, affecting fish, shellfish and plant species. Cape Verde is widely recognised as one of the most diverse marine environments in the world, including a globally-important coral reef.

 

AquaInSilico's technology will be used to create wastewater treatment processes to recycle nutrients as biofertilisers, as well as improving water quality to the islanders. Partners in the project include a leading wastewater company with experience in running projects in Cape Verde and other relevant organisations.

 

The highly competitive selection of Phos-Value as a UNDP Ocean Innovator represents important validation of the technology being developed by AquaInSilico, a spin-off of NOVA University Lisbon, NOVA School of Science and Technology ("FCT NOVA"). The Company received an EIT RawMaterials grant from the European Union's European Institute of Innovation and Technology last year to further develop its tools to optimise wastewater treatment.

 

The Company's software uses a mathematically modelled biological approach to improve phosphorus removal, based on deep understanding and controlling the operating variables that result from biological and chemical processes. Because of this, its algorithms can detect problems, often before they can be diagnosed by humans.

 

As a result, the technology has broad applicability, with the potential to allow companies, such as oil groups, brewers, pulp, paper, steel makers, food processing and waste recovery businesses, as well as wastewater treatment plants, to tune and adapt their treatment systems more effectively. It is expected to save them up to 25 per cent of their operating costs.

 

 

Frontier IP holds a 29 per cent equity stake in AqualnSilico. The Company was established to develop and commercialise the research of Dr Jorge Santos, Dr Mariana Matos and Professor Maria Ascensão Reis of FCT NOVA. This team had developed several research projects in environmental and industrial bioengineering in collaboration with several worldwide industry players.

 

The UNDP Ocean Innovation Challenge was established last year to identify, finance, advise and mentor innovative, entrepreneurial, and creative approaches to ocean and coastal restoration and protection.

 

 

AquaInSilico co-founder Dr Jorge Santos said: " Our team is very excited to be joining the United Nations Development Programme tackling ocean and coastal restoration and contributing to the sustainable development of the Cape Verde's wastewater industry with our digital tools and expertise. The motto for Phos-Value project is: 'Together we can recycle wastewater and nutrients to save oceans."

 

Frontier IP Chief Executive Officer Neil Crabb said: "We are delighted AquaInSilico is involved in this important United Nations Development Programme to conserve the marine environment around Cape Verde. The grant award represents a strong validation of the Company's technology and the progress it has made."

 

ENQUIRIES

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / George Payne

 

 

ABout frontier IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of hands-on commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology is validated and meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

ABOUT REACH ANNOUNCEMENTS

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

 

 

 

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFZGGFVLKGMZG
Date   Source Headline
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.